ArticleThe British journal of ophthalmology2007
Mycophenolate mofetil in the treatment of uveitis in children.
Article in The British journal of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05540743 (The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Cohort), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of Anti-TNF Alpha Agents in the Treatment of JIA- Associated Uveitis in a Pediatric Cohort
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.Rheumatology international · 2012Guideline
- Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry.Pediatric rheumatology online journal · 2016Trial
- Trial
- A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis.Translational vision science & technology · 2022Article
- Biologic therapies for juvenile idiopathic arthritis-associated uveitis.Frontiers in ophthalmology · 2022Review
- Management Strategies of Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis: Current Perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.Annals of eye science · 2021Article
- An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017Article
- Juvenile idiopathic arthritis-associated uveitis.Pediatric rheumatology online journal · 2016Review
- Uveitis in Children: Diagnosis and Management.Indian journal of pediatrics · 2016Review
- The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis.Paediatric drugs · 2015Review
- Uveitis associated with juvenile idiopathic arthritis.Nature reviews. Rheumatology · 2015Review
- [Therapy of intermediate uveitis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2014Article
- Treatment of uveitis associated with juvenile idiopathic arthritis.Current rheumatology reports · 2014Review
- Response of pediatric uveitis to tumor necrosis factor-α inhibitors.The Journal of rheumatology · 2013Article
- Paediatric use of mycophenolate mofetil.British journal of clinical pharmacology · 2013Review
- Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2011Article
- Mycophenolate mofetil monotherapy in the management of paediatric uveitis.Eye (London, England) · 2011Article
- Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.International ophthalmology · 2011Review
- Adalimumab (humira™) in ophthalmology: a review of the literature.Middle East African journal of ophthalmology · 2010Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycophenolate mofetil (MMF) is a new immunosuppressive agent that effectively controls the intraocular inflammation in adults. PURPOSE: To assess the efficacy of MMF in uveitis in children and to analyse the possible side effects. PARTICIPANTS AND
methodsA retrospective analysis was carried out on 17 children (32 eyes) with intraocular inflammation treated with MMF and followed up at the University Eye Hospital Tuebingen, Tuebingen, Germany, between 2000 and 2005. All children had chronic non-infectious uveitis and received MMF for at least 6 months. All patients were given steroids or other immunosuppressive agents before initiating treatment with MMF.
results17 children (10 boys and 7 girls) with a mean age of 8 (range 2-13) years at the onset of uveitis were examined. The average duration of follow-up after initiation of MMF was 3 (range 2-5) years. A steroid-sparing effect was achieved in 88% of the patients. The oral prednisolone was successfully discontinued in 41% children and reduced to a daily dose of < or =5 mg in 47% of the children. 24% of the patients remained relapse-free during the treatment, but a reduction in the relapse rate was observed in all other patients except one. Visual acuity was increased or maintained in 13 children (76%). Mild side effects (headache, rash, gastrointestinal discomfort) occurred in 7 patients (41%) and were the cause of discontinuation of MMF in 1 patient.
conclusionThe results of our study are encouraging and suggest that MMF is an effective agent also in the treatment for uveitis in children, with marked steroid-sparing potential and an acceptable side effect profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.